GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals

Detalhes bibliográficos
Autor(a) principal: Batista, Mariana Nogueira [UNESP]
Data de Publicação: 2018
Outros Autores: Silva Sanches, Paulo Ricardo da [UNESP], Carneiro, Bruno Moreira [UNESP], Silva Braga, Ana Claudia [UNESP], Fernandes Campos, Guilherme Rodrigues [UNESP], Chilli, Eduardo Maffud [UNESP], Rahal, Paula [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1038/s41598-018-32176-w
http://hdl.handle.net/11449/166341
Resumo: In recent years, synthetic peptides have been considered promising targets for drug development that possess low side-effects, are cost-effective and are susceptible to rational design. Hecate was initially described as a potent bacterial inhibitor and subsequently as an anticancer drug with functions related to its lipid interaction property. Viruses, such as hepatitis C virus (HCV), have a lipid-dependent life cycle and could be affected by Hecate in many ways. Here, we assessed modifications on Hecate's N-terminus region and its effects on HCV and hepatotoxicity. Gallic acid-conjugated Hecate was the most efficient Hecate-derivative, presenting high potential as an antiviral and inhibiting between 50 to 99% of all major steps within the HCV infectious cycle. However, the most promising aspect was GA-Hecate's mechanism of action, which was associated with a balanced lipid interaction with the viral envelope and lipid droplets, as well as dsRNA intercalation, allowing for the possibility to affect other ssRNA viruses and those with a lipid-dependent cycle.
id UNSP_5179bfe1e251a3c4299ed99ed8c14bae
oai_identifier_str oai:repositorio.unesp.br:11449/166341
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antiviralsIn recent years, synthetic peptides have been considered promising targets for drug development that possess low side-effects, are cost-effective and are susceptible to rational design. Hecate was initially described as a potent bacterial inhibitor and subsequently as an anticancer drug with functions related to its lipid interaction property. Viruses, such as hepatitis C virus (HCV), have a lipid-dependent life cycle and could be affected by Hecate in many ways. Here, we assessed modifications on Hecate's N-terminus region and its effects on HCV and hepatotoxicity. Gallic acid-conjugated Hecate was the most efficient Hecate-derivative, presenting high potential as an antiviral and inhibiting between 50 to 99% of all major steps within the HCV infectious cycle. However, the most promising aspect was GA-Hecate's mechanism of action, which was associated with a balanced lipid interaction with the viral envelope and lipid droplets, as well as dsRNA intercalation, allowing for the possibility to affect other ssRNA viruses and those with a lipid-dependent cycle.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)UNESP Sao Paulo State Univ, Inst Biosci Language & Exact Sci, Sao Jose Do Rio Preto, SP, BrazilUNESP Sao Paulo State Univ, Inst Chem, Araraquara, SP, BrazilUNESP Sao Paulo State Univ, Inst Biosci Language & Exact Sci, Sao Jose Do Rio Preto, SP, BrazilUNESP Sao Paulo State Univ, Inst Chem, Araraquara, SP, BrazilFAPESP: 2013/07600-3FAPESP: 2015/23244-8FAPESP: 2016/02174-4FAPESP: 2017/00287-9Nature Publishing GroupUniversidade Estadual Paulista (Unesp)Batista, Mariana Nogueira [UNESP]Silva Sanches, Paulo Ricardo da [UNESP]Carneiro, Bruno Moreira [UNESP]Silva Braga, Ana Claudia [UNESP]Fernandes Campos, Guilherme Rodrigues [UNESP]Chilli, Eduardo Maffud [UNESP]Rahal, Paula [UNESP]2018-11-30T04:09:35Z2018-11-30T04:09:35Z2018-09-25info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article12application/pdfhttp://dx.doi.org/10.1038/s41598-018-32176-wScientific Reports. London: Nature Publishing Group, v. 8, 12 p., 2018.2045-2322http://hdl.handle.net/11449/16634110.1038/s41598-018-32176-wWOS:000445570700022WOS000445570700022.pdf79910823626712120000-0001-5693-6148Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengScientific Reportsinfo:eu-repo/semantics/openAccess2024-01-12T06:28:48Zoai:repositorio.unesp.br:11449/166341Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T22:47:56.961482Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals
title GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals
spellingShingle GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals
Batista, Mariana Nogueira [UNESP]
title_short GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals
title_full GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals
title_fullStr GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals
title_full_unstemmed GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals
title_sort GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals
author Batista, Mariana Nogueira [UNESP]
author_facet Batista, Mariana Nogueira [UNESP]
Silva Sanches, Paulo Ricardo da [UNESP]
Carneiro, Bruno Moreira [UNESP]
Silva Braga, Ana Claudia [UNESP]
Fernandes Campos, Guilherme Rodrigues [UNESP]
Chilli, Eduardo Maffud [UNESP]
Rahal, Paula [UNESP]
author_role author
author2 Silva Sanches, Paulo Ricardo da [UNESP]
Carneiro, Bruno Moreira [UNESP]
Silva Braga, Ana Claudia [UNESP]
Fernandes Campos, Guilherme Rodrigues [UNESP]
Chilli, Eduardo Maffud [UNESP]
Rahal, Paula [UNESP]
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Batista, Mariana Nogueira [UNESP]
Silva Sanches, Paulo Ricardo da [UNESP]
Carneiro, Bruno Moreira [UNESP]
Silva Braga, Ana Claudia [UNESP]
Fernandes Campos, Guilherme Rodrigues [UNESP]
Chilli, Eduardo Maffud [UNESP]
Rahal, Paula [UNESP]
description In recent years, synthetic peptides have been considered promising targets for drug development that possess low side-effects, are cost-effective and are susceptible to rational design. Hecate was initially described as a potent bacterial inhibitor and subsequently as an anticancer drug with functions related to its lipid interaction property. Viruses, such as hepatitis C virus (HCV), have a lipid-dependent life cycle and could be affected by Hecate in many ways. Here, we assessed modifications on Hecate's N-terminus region and its effects on HCV and hepatotoxicity. Gallic acid-conjugated Hecate was the most efficient Hecate-derivative, presenting high potential as an antiviral and inhibiting between 50 to 99% of all major steps within the HCV infectious cycle. However, the most promising aspect was GA-Hecate's mechanism of action, which was associated with a balanced lipid interaction with the viral envelope and lipid droplets, as well as dsRNA intercalation, allowing for the possibility to affect other ssRNA viruses and those with a lipid-dependent cycle.
publishDate 2018
dc.date.none.fl_str_mv 2018-11-30T04:09:35Z
2018-11-30T04:09:35Z
2018-09-25
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1038/s41598-018-32176-w
Scientific Reports. London: Nature Publishing Group, v. 8, 12 p., 2018.
2045-2322
http://hdl.handle.net/11449/166341
10.1038/s41598-018-32176-w
WOS:000445570700022
WOS000445570700022.pdf
7991082362671212
0000-0001-5693-6148
url http://dx.doi.org/10.1038/s41598-018-32176-w
http://hdl.handle.net/11449/166341
identifier_str_mv Scientific Reports. London: Nature Publishing Group, v. 8, 12 p., 2018.
2045-2322
10.1038/s41598-018-32176-w
WOS:000445570700022
WOS000445570700022.pdf
7991082362671212
0000-0001-5693-6148
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Scientific Reports
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 12
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv Web of Science
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808129463018323968